Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

1.

Prevention of HIV-1 infection with early antiretroviral therapy.

Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, Godbole SV, Mehendale S, Chariyalertsak S, Santos BR, Mayer KH, Hoffman IF, Eshleman SH, Piwowar-Manning E, Wang L, Makhema J, Mills LA, de Bruyn G, Sanne I, Eron J, Gallant J, Havlir D, Swindells S, Ribaudo H, Elharrar V, Burns D, Taha TE, Nielsen-Saines K, Celentano D, Essex M, Fleming TR; HPTN 052 Study Team..

N Engl J Med. 2011 Aug 11;365(6):493-505. doi: 10.1056/NEJMoa1105243.

2.

The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling study.

Powers KA, Ghani AC, Miller WC, Hoffman IF, Pettifor AE, Kamanga G, Martinson FE, Cohen MS.

Lancet. 2011 Jul 16;378(9787):256-68. doi: 10.1016/S0140-6736(11)60842-8.

3.

Treatment 2.0: catalysing the next phase of scale-up.

Hirnschall G, Schwartländer B.

Lancet. 2011 Jul 16;378(9787):209-11. doi: 10.1016/S0140-6736(11)60247-X. No abstract available.

PMID:
21353697
4.
5.

Scaling up the 2010 World Health Organization HIV Treatment Guidelines in resource-limited settings: a model-based analysis.

Walensky RP, Wood R, Ciaranello AL, Paltiel AD, Lorenzana SB, Anglaret X, Stoler AW, Freedberg KA; CEPAC-International Investigators..

PLoS Med. 2010 Dec 21;7(12):e1000382. doi: 10.1371/journal.pmed.1000382.

6.

The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States.

Long EF, Brandeau ML, Owens DK.

Ann Intern Med. 2010 Dec 21;153(12):778-89. doi: 10.7326/0003-4819-153-12-201012210-00004.

7.

Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study.

Montaner JS, Lima VD, Barrios R, Yip B, Wood E, Kerr T, Shannon K, Harrigan PR, Hogg RS, Daly P, Kendall P.

Lancet. 2010 Aug 14;376(9740):532-9. doi: 10.1016/S0140-6736(10)60936-1.

8.

United States global health policy: HIV/AIDS, maternal and child health, and The President's Emergency Plan for AIDS Relief (PEPFAR).

Leeper SC, Reddi A.

AIDS. 2010 Sep 10;24(14):2145-9. doi: 10.1097/QAD.0b013e32833cbb41.

PMID:
20606571
9.

Expanding access to HAART: a cost-effective approach for treating and preventing HIV.

Johnston KM, Levy AR, Lima VD, Hogg RS, Tyndall MW, Gustafson P, Briggs A, Montaner JS.

AIDS. 2010 Jul 31;24(12):1929-35. doi: 10.1097/QAD.0b013e32833af85d.

PMID:
20588171
10.

Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco.

Das M, Chu PL, Santos GM, Scheer S, Vittinghoff E, McFarland W, Colfax GN.

PLoS One. 2010 Jun 10;5(6):e11068. doi: 10.1371/journal.pone.0011068.

11.

Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis.

Donnell D, Baeten JM, Kiarie J, Thomas KK, Stevens W, Cohen CR, McIntyre J, Lingappa JR, Celum C; Partners in Prevention HSV/HIV Transmission Study Team..

Lancet. 2010 Jun 12;375(9731):2092-8. doi: 10.1016/S0140-6736(10)60705-2.

12.

HIV-1 transmission after cessation of early antiretroviral therapy among men having sex with men.

Rieder P, Joos B, von Wyl V, Kuster H, Grube C, Leemann C, Böni J, Yerly S, Klimkait T, Bürgisser P, Weber R, Fischer M, Günthard HF; Swiss HIV Cohort Study..

AIDS. 2010 May 15;24(8):1177-83. doi: 10.1097/QAD.0b013e328338e4de.

PMID:
20386427
13.

Evolutionary dynamics of complex networks of HIV drug-resistant strains: the case of San Francisco.

Smith RJ, Okano JT, Kahn JS, Bodine EN, Blower S.

Science. 2010 Feb 5;327(5966):697-701. doi: 10.1126/science.1180556.

14.

Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection.

Gill VS, Lima VD, Zhang W, Wynhoven B, Yip B, Hogg RS, Montaner JS, Harrigan PR.

Clin Infect Dis. 2010 Jan 1;50(1):98-105. doi: 10.1086/648729.

15.

HIV prevention cost-effectiveness: a systematic review.

Galárraga O, Colchero MA, Wamai RG, Bertozzi SM.

BMC Public Health. 2009 Nov 18;9 Suppl 1:S5. doi: 10.1186/1471-2458-9-S1-S5. Review.

16.

The cost effectiveness of home-based provision of antiretroviral therapy in rural Uganda.

Marseille E, Kahn JG, Pitter C, Bunnell R, Epalatai W, Jawe E, Were W, Mermin J.

Appl Health Econ Health Policy. 2009;7(4):229-43. doi: 10.2165/11318740-000000000-00000.

17.

The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals.

HIV-CAUSAL Collaboration., Ray M, Logan R, Sterne JA, Hernández-Díaz S, Robins JM, Sabin C, Bansi L, van Sighem A, de Wolf F, Costagliola D, Lanoy E, Bucher HC, von Wyl V, Esteve A, Casbona J, del Amo J, Moreno S, Justice A, Goulet J, Lodi S, Phillips A, Seng R, Meyer L, Pérez-Hoyos S, García de Olalla P, Hernán MA.

AIDS. 2010 Jan 2;24(1):123-37. doi: 10.1097/QAD.0b013e3283324283.

18.

Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study.

Wood E, Kerr T, Marshall BD, Li K, Zhang R, Hogg RS, Harrigan PR, Montaner JS.

BMJ. 2009 Apr 30;338:b1649. doi: 10.1136/bmj.b1649.

19.

Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis.

Attia S, Egger M, Müller M, Zwahlen M, Low N.

AIDS. 2009 Jul 17;23(11):1397-404. doi: 10.1097/QAD.0b013e32832b7dca. Review.

PMID:
19381076
20.

Treating our way out of the HIV pandemic: could we, would we, should we?

Garnett GP, Baggaley RF.

Lancet. 2009 Jan 3;373(9657):9-11. doi: 10.1016/S0140-6736(08)61698-0. No abstract available.

PMID:
19038439
Items per page

Supplemental Content

Support Center